| Literature DB >> 23519018 |
Chao Ma1, Ann F Cheung, Thinle Chodon, Richard C Koya, Zhongqi Wu, Charles Ng, Earl Avramis, Alistair J Cochran, Owen N Witte, David Baltimore, Bartosz Chmielowski, James S Economou, Begonya Comin-Anduix, Antoni Ribas, James R Heath.
Abstract
UNLABELLED: Adoptive cell transfer (ACT) of genetically engineered T cells expressing cancer-specific T-cell receptors (TCR) is a promising cancer treatment. Here, we investigate the in vivo functional activity and dynamics of the transferred cells by analyzing samples from 3 representative patients with melanoma enrolled in a clinical trial of ACT with TCR transgenic T cells targeted against the melanosomal antigen MART-1. The analyses included evaluating 19 secreted proteins from individual cells from phenotypically defined T-cell subpopulations, as well as the enumeration of T cells with TCR antigen specificity for 36 melanoma antigens. These analyses revealed the coordinated functional dynamics of the adoptively transferred, as well as endogenous, T cells, and the importance of highly functional T cells in dominating the antitumor immune response. This study highlights the need to develop approaches to maintaining antitumor T-cell functionality with the aim of increasing the long-term efficacy of TCR-engineered ACT immunotherapy. SIGNIFICANCE: A longitudinal functional study of adoptively transferred TCR–engineered lymphocytes yielded revealing snapshots for understanding the changes of antitumor responses over time in ACT immunotherapy of patients with advanced melanoma. ©2013 AACR.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23519018 PMCID: PMC3716460 DOI: 10.1158/2159-8290.CD-12-0383
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397